To assess the role of Bcl-X L and its splice derivative, Bcl-X S , in staurosporine-induced cell death, we used a dopaminergic cell line, MN9D, transfected with bcl-x L (MN9D/Bcl-X L ), bcl-x S (MN9D/Bcl-X S ), or control vector (MN9D/Neo). Only 8.6% of MN9D/Neo cells survived after 24 h of 1 M staurosporine treatment. Caspase activity was implicated because a caspase inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk), attenuated staurosporine-induced cell death. Bcl-X L rescued MN9D cells from death (89.4% viable cells), whereas Bcl-X S had little or no effect. Bcl-X L prevented morphologically apoptotic changes as well as cleavage of poly(ADP-ribose)polymerase (PARP) induced by staurosporine. It is interesting that a small Bax-immunoreactive protein appeared 4 -8 h after PARP cleavage in MN9D/Neo cells. The appearance of the small Baximmunoreactive protein, however, may be cell type-specific as it was not observed in PC12 cells after staurosporine treatment. The sequential cleavage of PARP and the appearance of the small Bax-immunoreactive protein in MN9D cells were blocked either by Z-VAD-fmk or by Bcl-X L . Thus, our present study suggests that Bcl-X L but not Bcl-X S prevents staurosporine-induced apoptosis by inhibiting the caspase activation that may be directly or indirectly responsible for the appearance of the small Bax-immunoreactive protein in some types of neurons.
Apoptosis is a highly conserved form of cell death that might have evolved as a regulatory mechanism for development, cellular homeostasis, and certain pathological conditions (Wyllie, 1993; Thompson, 1995) . It is typically accompanied by a series of characteristic morphological and biochemical changes such as cytoplasmic shrinkage, membrane blebbing, chromatin condensation, and DNA laddering into oligonucleosomal-sized doublestranded fragments. Neuronal cell death is also a prominent feature of vertebrate development (Oppenheim, 1991) . Depending on the location, ϳ20 -80% of neurons in a given developing population die, possibly by apoptotic processes. Furthermore, accumulating evidence indicates that particular sets of neuronal cells associated with neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's disease die of apoptosis (Su et al., 1994; Portera-Cailliau et al., 1995; Stern, 1996) . Therefore, it is of clinical interest to investigate the mechanism(s) underlying neuronal cell death associated with such devastating diseases in the CNS.
Among many proposed mechanisms, activation of interleukin-1-␤-converting enzyme (ICE)-like proteases seems to be a required element of apoptotic cell death in many paradigms (Martin and Green, 1995) . It has been demonstrated that ICE has significant sequence homology to Ced-3, first identified as a positive regulator of cell death during the development of the nematode Caenorhabditis elegans . Overexpression of ICE in fibroblasts resulted in apoptosis (Miura et al., 1993) . Subsequently, involvement of ICE in neuronal cell death was demonstrated in vertebrates (Gagliardini et al., 1994) . These findings have been followed by the discovery of several ICE/Ced-3-like homologues, recently termed caspases (Alnemri et al., 1996) . Proteolytic activation of one caspase may lead to proteolytic processing of the next caspase involved, resulting in a cas-cade of protease activation (Martin and Green, 1995) . Diverse cellular proteins, including poly(ADP-ribose)-polymerase (PARP), serve as substrates for these cascades of caspase activation (Cryns and Yuan, 1998) . In addition to caspases, overexpression of several other proteases was also shown to be associated with apoptotic death. These include granzyme B, chymotrypsin, proteinase K, and trypsin (Shi et al., 1992; Williams and Henkart, 1994) . It is interesting that granzyme B, a serine protease, initiates apoptosis by proteolytic processing and activation of ICE/Ced-3 proteases in hemopoietic cell types (Darmon et al., 1995) . This raises the possibility that there may exist several other pathways in which the temporal interaction among many different proteases is centrally regulated during apoptosis in certain cell types.
Numerous recent findings have demonstrated that Bcl-2 acts as a negative regulator of apoptosis induced by various stresses (Reed, 1997) . Several other members of the Bcl-2 family have also been identified. For example, Bcl-X L , one member of the Bcl-2 family, is the major form of bcl-x mRNA expressed during embryonic and postnatal development of murine tissues (Boise et al., 1993; Gonzalez-Garcia et al., 1994) . Like Bcl-2, its 233-amino acid product has been shown to localize to the mitochondrial outer membrane and perinuclear envelope. As a result of alternative splicing of bcl-x mRNA, Bcl-X S encodes a 178-amino acid protein, which lacks a stretch of internal 63 amino acids that make up the region of highest homology to Bcl-2. Overexpression of Bcl-X L can prevent apoptosis, whereas expression of Bcl-X S enhances apoptotic cell death in several cases (Boise et al., 1993) . Many Bcl-2 family members, including Bcl-X L , show widespread expression in the developing and adult brain (Merry and Korsmeyer, 1997) . The physiological role of these proteins in neuronal life and death has been shown in many neuronal cell types of the CNS. However, their roles have not been extensively explored in dopaminergic neuronal cell death, which is intimately associated with the development of Parkinson's disease.
A wide range of cell types, including dopaminergic neuronal cells, undergo apoptosis after treatment with a broad-spectrum protein kinase inhibitor, staurosporine (Jacobson et al., 1993; Oh et al., 1997) . Therefore, we set out in the present experiments to characterize further staurosporine-induced cell death and to elucidate the effects of Bcl-X L and Bcl-X S on the survival of murine dopaminergic neuronal cells following staurosporine treatment. Comparisons were made with a pan-caspase inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk).
MATERIALS AND METHODS

Cell culture and drug treatments
MN9D cells stably transfected with a eukaryotic expression vector, CMV/bcl-x L (MN9D/Bcl-X L ), CMV/bcl-x S (MN9D/ Bcl-X S ), or control CMV/Neo (MN9D/Neo), were established and maintained. To test the effects of staurosporine, cells from each clone were plated at a density of 2 ϫ 10 4 cells on 25 g/ml poly-D-lysine-coated 48-well plates (Corning) and maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (GibcoBRL) and 250 g/ml G-418 (complete culture medium) for 3 days in an incubator with an atmosphere of 10% CO 2 at 37°C. Cells were subsequently switched to serum-free N2 medium containing the various experimental reagents and further incubated for the indicated intervals. Reagents included staurosporine (0.25-1.0 M; Sigma), iodoacetamide (2.5-10 M; Sigma), Z-VAD-fmk (100 M; Enzyme Systems Products), and cycloheximide (0.25-1.0 g/ml; Sigma).
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay
Following incubation with various experimental reagents, the rate of cell survival was assessed by colorimetric measurement of MTT reduction, which is an indicator of the pyridine nucleotide redox state of the cell, as described previously (Shearman et al., 1994) . In brief, after the indicated incubation times, the MTT solution was added to a final concentration of 1 mg/ml, and the cells were incubated for 2 h at 37°C, followed by lysis in 20% sodium dodecyl sulfate in 50% aqueous N,Ndimethylformamide for 24 h. The optical density of the dissolved formazan grains within the cells was measured at 540 nm on a microplate reader (Molecular Devices). Values from each treatment were calculated as a percentage relative to untreated control (100% survival).
Electron microscopy
Both MN9D/Neo and MN9D/Bcl-X L cells plated at a density of 7.0 ϫ 10 4 on poly-D-lysine-coated 24-well plates were treated with 1.0 M staurosporine for various intervals. After various incubation times (up to 24 h of treatment), cells were fixed in 2% paraformaldehyde and 2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for at least 12 h at 4°C and then postfixed in 1% osmium tetroxide/1.5% ferrocyanide solution for 30 min at room temperature. Cells were dehydrated in a graded series of ethanols, embedded in Epon resin, and heatpolymerized. Epon blocks were cut using a Reichert-Jung Ultracut S (Leica) and double-stained with uranyl acetate and lead citrate. Sections were examined using a Zeiss EM 902A transmission electron microscope.
Immunoblot analysis
For the characterization of stable cell lines, 5-10 ϫ 10 6 MN9D/Neo, MN9D/Bcl-X L , and MN9D/Bcl-X S cells were washed with ice-cold phosphate-buffered saline and lysed on ice in a lysis buffer containing 50 mM Tris (pH 7.0), 2 mM EDTA, 1.0% Triton X-100, 2 mM phenylmethylsulfonyl fluoride, and 10 g/ml aprotinin. Subsequently, lysates were centrifuged at 13,000 g for 10 min. The protein content of the resulting supernatant was measured using the Bio-Rad protein assay kit. For analyzing PARP and Bax, MN9D/Neo, MN9D/ Bcl-X L , MN9D/Bcl-X S , and PC12 cells were plated at a density of 1 ϫ 10 6 on poly-D-lysine-coated P-100 culture plates (Corning) and grown in complete culture medium for 3 days before drug treatment. At the various times indicated, cells were incubated in a lysis buffer and further processed for immunoblot analysis as described above. Equal amounts of soluble protein (40 -75 g) were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. Proteins were transblotted onto prewetted polyvinylidene difluoride-nitrocellulose filters (Bio-Rad). Primary antibodies used were rabbit polyclonal anti-Bcl-X, which recognizes both Bcl-X L and Bcl-X S forms (1:3,000); mouse monoclonal anti-PARP (1: 10,000; a generous gift from Dr. G. G. Poirier); rabbit polyclonal anti-mouse Bax, raised against amino acid residues 43-61 of mouse Bax [1:2,000 (Krajewski et al., 1994) ]; and rabbit polyclonal anti-Bax directed against amino acid residues 11-30 (N-20, 1:1,000; Santa Cruz). Specific bands of interest were detected by enhanced chemiluminescence (ECL; Amersham) as recommended by the manufacturer.
RESULTS
Characterization of Bcl-X L -and Bcl-X S -expressing MN9D cell lines by immunoblotting
To assess the potential role of Bcl-X L and Bcl-X S in the dopaminergic neuronal cell line MN9D, cells were transfected with CMV/bcl-x L (MN9D/Bcl-X L ), CMV/ bcl-x S (MN9D/Bcl-X S ), or the parental vector CMV/Neo (MN9D/Neo). Two separately derived clonal cell lines expressing the highest mRNA levels of bcl-x L and two for bcl-x S were selected through RT-PCR (data not shown) and further analyzed by immunoblot analysis. The analysis demonstrated that MN9D/Bcl-X L clone 14 contained higher levels of protein than clone 22, whereas Bcl-X S clone 40 expressed higher levels of the Bcl-X S protein than clone 25 (Fig. 1A) .
Characterization and quantification of staurosporine-induced cell death
Staurosporine treatment induced cell death in MN9D/ Neo cells as determined by the MTT reduction assay.
Approximately half of the MN9D/Neo cells died 10 -12 h following 1 M staurosporine treatment. When treated with 0.25-1.0 M staurosporine for 24 h, cells from MN9D/Bcl-X L clone 14 remained viable following staurosporine treatment (Fig. 1B) . Similar patterns were observed in MN9D/Bcl-X L clone 22 (data not shown). The two MN9D/Bcl-X S clones, on the other hand, showed cell death patterns relatively similar to that of MN9D/ Neo cells, regardless of the level of Bcl-X S expression. When morphological changes were examined by light microscopy, treatment of cells with staurosporine initially resulted in neurite arborization within 4 -6 h (data not shown; Oh et al., 1997) . Thereafter, MN9D/Neo cells exhibited typical apoptotic changes such as shrinkage of the cytoplasmic membrane and nuclei (Fig. 2B) . Staurosporine treatment led to the degeneration of neurite arborizations of MN9D/Neo cells as well. Quite similar patterns of morphological changes were observed in the two MN9D/Bcl-X S cells (data not shown). It is interesting that both MN9D/Bcl-X L clone 14 and clone 22 cells displayed more rounded cell bodies even before drug treatment ( Fig. 2D ; data not shown for clone 22). Following staurosporine treatment, MN9D/Bcl-X L cells maintained extensive arborization of neurites, yet there was no blebbing of the plasma membrane, retaining intact cell bodies and nuclei even after 24 h of treatment (Fig. 2E ). When their viability was assessed by the in situ MTT reduction assay, the majority of surviving MN9D/ Bcl-X L cells showed dark formazan grains within the cytoplasm, demonstrating that the mitochondria of these cells were still functionally intact ( Fig. 2F ; compare with MN9D/Neo cells in Fig. 2C ).
Electron microscopic analysis of staurosporineinduced morphology
To examine the ultrastructural changes during staurosporine-induced cell death in greater detail, both MN9D/ Neo and MN9D/Bcl-X L clone 14 cells were treated with 1 M staurosporine for various times and analyzed by electron microscopy. Within 4 -6 h of treatment, staurosporine induced the appearance of perinuclear chromatin condensation in a few MN9D/Neo cells (data not shown). By 16 -24 h, the majority of shrunken MN9D/ Neo cells exhibited chromatin condensation, which was sharply delineated around the inner surface of the nuclear envelope and was often accompanied by nuclear convolution (Fig. 3B) . In some cells, nuclear fragments of varying size and chromatin content were obvious. Cytoplasmic organelles, including mitochondria and endoplasmic reticulum, remained largely intact. However, MN9D/Bcl-X L cells treated with 1 M staurosporine for up to 24 h displayed no discernible changes typical of apoptosis observed in MN9D/Neo cells ( Fig. 3C ; compare with untreated control shown in Fig. 3A ).
Sequential cleavage of PARP and appearance of a small Bax-immunoreactive protein
Previously, it has been shown that PARP cleavage by activated caspases is one of the common events associ- ated with many cases of apoptosis (Lazebnik et al., 1994; Cryns and Yuan, 1998) . We therefore performed an experiment to assess whether staurosporine induces cleavage of PARP in MN9D/Neo cells and also whether overexpression of Bcl-X L blocks this event. Both MN9D/Neo and MN9D/Bcl-X L cells were treated with 1 M staurosporine for various times. As shown in Fig.  4A , the formation of the 85-kDa cleaved PARP fragment was seen as early as 12 h in MN9D/Neo cell lysates and continued thereafter. In the course of examining the expression level of cell death-associated proteins, we found that our antibodies against Bax recognized both the intact 21-kDa Bax and a smaller band of 18 kDa that appeared at least 4 -8 h after PARP cleavage during the process of staurosporine-induced cell death (Fig. 4B) . The intensity of this 18-kDa band increased while in parallel that of the intact 21-kDa Bax band decreased over time after exposure of cells to staurosporine. In certain experiments, this 18-kDa band appeared within 2-4 h after PARP cleavage (data not shown). The generation of the cleaved fragment of PARP was abolished in MN9D/Bcl-X L but not MN9D/Bcl-X S cells (Fig. 5A) . Similarly, the small Bax-immunoreactive band was seen in staurosporine-treated MN9D/Neo and MN9D/Bcl-X S cells, whereas this band was completely abolished in MN9D/Bcl-X L cells (Fig. 5B) .
Properties of the small Bax-immunoreactive protein
When cells were treated with up to 1 g/ml cycloheximide, a protein synthesis inhibitor, together with staurosporine, appearance of the 18-kDa Bax-immunoreactive band was still observed (Fig. 6A) . As shown in Fig.  6B , this 18-kDa band was not detected by an antibody directed against the N-terminal amino acid residues 1-30 of Bax, whereas the intensity of the intact 21-kDa band decreased over time, suggesting that it may be a cleaved form of Bax. Treatment of MN9D/Neo cells with 5 M iodoacetamide did not prevent staurosporine-induced cell death (Fig. 7A) . Similarly, staurosporine-induced cleavage of PARP was not blocked in the presence of iodoacetamide (data not shown). In contrast, treatment with 100 M Z-VAD-fmk markedly attenuated staurosporine-induced cell death (12.6 vs. 64.3% cell survival), suggesting that the activation of Z-VAD-fmk-sensitive but iodoacetamide-insensitive cysteine protease(s) is implicated in this cell death model. Although there existed a lag period of at least 4 -8 h following cleavage of PARP, the appearance of the 18-kDa band was blocked in the presence of 100 M Z-VAD-fmk but not iodoacetamide (Fig. 7B) . It is interesting that this 18-kDa band did not appear in PC12 cells up to 6 -12 h after staurosporine treatment, although Ͼ80% of PC12 cells died of apoptosis under these conditions (Fig. 8) .
DISCUSSION
Our studies have demonstrated a protective role for Bcl-X L in staurosporine-induced apoptosis of a dopaminergic neuronal cell line. Protection of staurosporineinduced apoptosis by Bcl-X L overexpression was confirmed not only by the quantitative measurement of dehydrogenase activity of active mitochondria but also by the examination of cellular morphology using both light and electron microscopy. Our present studies have also shown that overexpression of Bcl-X L possibly affects processes at or upstream of caspase activation because Bcl-X L blocked the sequential cleavage of PARP and the appearance of a small Bax-immunoreactive protein in 
FIG. 4.
Cleavage of PARP is followed by the appearance of an 18-kDa Bax-immunoreactive protein following staurosporine treatment. MN9D/Neo cells were treated with 1 M staurosporine. At the indicated intervals, cells were lysed and processed for immunoblot analysis as described in Materials and Methods. Specific bands of (A) PARP and (B) Bax were detected with mouse monoclonal antibody raised against PARP (1:10,000, a generous gift from Dr. G. G. Poirier) and polyclonal antibodies raised against amino acid residues 43-61 of mouse Bax [1:2,000 (Krajewski et al., 1994) ], respectively. Note the appearance of a small Bax-immunoreactive band at least 4 -8 h after PARP cleavage in this particular set of experiments.
FIG. 5.
Sequential cleavage of PARP and the appearance of the 18-kDa Bax-immunoreactive protein are blocked by Bcl-X L but not by Bcl-X S . MN9D/Neo, MN9D/Bcl-X L clone 14, and MN9D/ Bcl-X S clone 40 cells were treated with 1 M staurosporine for the indicated intervals. Immunoblot analysis was performed as described in Fig. 4 . Both (A) PARP cleavage and (B) appearance of the 18-kDa Bax-immunoreactive band were blocked by Bcl-X L but not by Bcl-X S .
staurosporine-treated MN9D cells. That Z-VAD-fmk but not iodoacetamide was able to block cell death and its accompanying PARP cleavage in our cell line raises the possibility that the cysteine protease responsible for cell death in MN9D cells may be different from the proteases implicated in nonneuronal systems (Kaufmann et al., 1993; Casciola-Rosen et al., 1994) , perhaps analogous to the recently proposed protein homologous to human caspase-3 in the rat brain (Ni et al., 1997) .
During the course of staurosporine treatment, both MN9D/Neo and MN9D/Bcl-X L cells initially went through similar morphological changes such as neurite arborization and formation of neuritic varicosities. In the later stages, however, MN9D/Bcl-X L cells were able to maintain the integrity of their rounded cell bodies, without accompanying shrinkage of cytoplasmic membrane and nuclei. As it has been recently demonstrated that Bcl-X L promotes cell survival by regulating the electrical and osmotic homeostasis within the cells (Vander Heiden et al., 1997) , the intrinsic ability of Bcl-X L in regulating the trafficking of various ions somehow results in better survival after staurosporine treatment, which possibly disturbs a balance of ions critical for cell life and death. It is interesting that even before drug treatment, a clear difference in morphology was observed between MN9D/Neo and MN9D/Bcl-X L clones in that MN9D/ Bcl-X L cells displayed a more round morphology (compare Fig. 2A with D) . Because Bcl-X L has been shown to form ion channels in membranes (Muchmore et al., 1996; Minn et al., 1997) , perhaps the rounded morphology observed in these cells reflects the role of Bcl-X L as a regulator of ion fluxes, causing an increased ratio of cell volume to cell area within MN9D cells and possibly increasing the threshold required for effective cell death stimulation.
It is interesting that overexpression of Bcl-X S did not enhance staurosporine-induced apoptosis, unlike results from some other cell death systems (Boise et al., 1993; Dole et al., 1996; Ealovega et al., 1996; Pena et al., 1996) . Similarly, acceleration of cell death by Bcl-X S was not observed in MN9D cells following treatment with various other drugs, including 1-methyl-4-phenylpyridinium ion, 6-hydroxydopamine, and etoposide (data not shown). Considering the previous finding that the expression of bcl-x S mRNA and Bcl-X S protein was undetectable in developing mouse tissues and experi- Immunoblot analysis was performed using polyclonal antibodies raised against amino acid residues 43-61 of Bax as described in Fig. 4.   FIG. 6 . Properties of the 18-kDa Bax-immunoreactive band. A: MN9D/Neo cells were treated with 1 g/ml cycloheximide (CHX; a protein synthesis inhibitor), together with 1 M staurosporine (STS) for the indicated intervals. Immunoblot analysis for Bax was performed using polyclonal antibodies raised against amino acid residues 43-61 of Bax. B: Following treatment of MN9D/ Neo cells with 1 M STS for the indicated intervals, immunoblot analysis was carried out using rabbit polyclonal antibodies directed against the N-terminal amino acid residues 11-30 of Bax (Santa Cruz). ROLE OF Bcl-X IN DOPAMINERGIC NEURONAL CELL DEATH mentally induced cell death of PC12 cells (GonzalezGarcia et al., 1994; Maroto and Perez-Polo, 1997) , it is reasonable to assume that the physiological role of Bcl-X S , if any, may be highly restricted.
We have found that an 18-kDa Bax-immunoreactive band appeared in staurosporine-induced apoptosis. In agreement with previous reports suggesting that Bax may be cleaved in cells following treatment with cytotoxic agents or infection with viruses (Thomas et al., 1996; Grandgirard et al., 1998) , our experiments using cycloheximide, a protein synthesis inhibitor, or N-terminal-specific antibodies against Bax make it less likely that this smaller form of Bax represents a Bax-related protein that is newly synthesized during cell death in MN9D cells (see Fig. 6 ). If this is the case, the staurosporine-induced 18-kDa band appears to be a product of specific proteolysis, because there is no smeared pattern of protein as judged from immunoblot analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. It is intriguing that our finding that this 18-kDa band does not appear in staurosporine-treated PC12 cells indicates that the appearance of this band is not a common event associated with apoptosis and may be cell typedependent.
It is important that we have also found that the appearance of the 18-kDa Bax-immunoreactive band is delayed by a few hours relative to PARP cleavage in staurosporine-treated MN9D cells. The finding that the sequential cleavage of PARP and the appearance of the 18-kDa Bax-immunoreactive band were blocked by treatment with Z-VAD-fmk makes it quite likely that the activation of the caspase responsible for PARP cleavage is directly or indirectly responsible for the activation of a downstream protease. This could be ascribed to the activation loop of proteases that eventually leads to the appearance of the 18-kDa band in staurosporine-induced MN9D cell death. As the N and C termini of Bax contain putative target sites for caspases, one at FIQD 33 2R and another at WIQD 154 2Q, it may be that the 18-kDa band is a direct product of caspase-mediated cleavage of 21-kDa Bax. Our study using antibodies directed against the N-terminal amino acid residues 11-30 of Bax indicates that the potential cleavage site is located at the N terminus of Bax. Considering the recent finding that there exists a stringency of substrate recognition motifs for known caspases (Thornberry et al., 1997) , the possibility cannot be ruled out, however, that activation of the noncaspase following Z-VAD-sensitive caspase activation results in N-terminal cleavage of Bax in MN9D cells. To understand the underlying significance of this event it remains to be determined whether the 18-kDa Bax-immunoreactive protein itself may play any functional role in the effector and/or degradation phases of apoptosis, analogous to that recently proposed for cleaved Bcl-2 (Cheng et al., 1997; Grandgirard et al., 1998) .
Recently, neuronal apoptosis has been proposed to be associated with Parkinson's disease (Mochizuki et al., 1996; Anglade et al., 1997; Tompkins et al., 1997) . Thus, our dopaminergic neuronal system may provide a model for evaluating the mechanism(s) underlying the functional role of Bcl-2-related family members in neuronal apoptotic cell death. Furthermore, studies of antiapoptotic genes, including Bcl-X L , may suggest strategies for improving the treatment of patients with Parkinson's disease (Thompson, 1995) .
